2024 Bladder Cancer Think Tank Meeting

Patient Voice Panel

Patient Voice Panel with BCAN Co-Founder Diane Zipursky Quale and patient advocates Angeline Glender, Richard Chaves, and Brent Ulbert

Meet the 2024 John Quale Travel Fellows

Meet the 2024 John Quale Travel Fellows with introduction by Scientific Review Group Chair, Max Kates, MD, Johns Hopkins Medicine

2023 Patient Centered Clinical Research Young Investigator Awardee

Rishi Sekar, MD, University of Michigan: Identifying individual and community-level drivers of disparities in bladder cancer clinical trials participation.

2023 Young Investigator Awardees

• Jonathan Chou, MD, PhD, University of California, San Francisco: Targeting advanced bladder cancer with NECTIN4-directed CAR T cell therapy
• Kathryn Gessner, MD, PhD, University of North Carolina at Chapel Hill: Dissecting the impact of E-cadherin loss on immune microenvironment and response to immune checkpoint blockade in plasmacytoid urothelial carcinoma
• Sean Clark-Garvey, MD, MPH, University of North Carolina at Chapel Hill: Exploring FGFR3 inhibition as a sensitizing agent to Nectin-4 ADC therapy in urothelial carcinoma
• Soonbum Park, PhD, Columbia University Medical Center: Investigating novel mechanisms and therapeutic options for metastatic bladder cancer

Bridging Evidence Generation to Practice in Bladder Cancer Care with Implementation Science

Co-Chairs: Kristian Stensland, MD, MPH, MS, University of Michigan and Elizabeth Guancial, MD, Florida Cancer Specialists and Research Institute

Research Update Session

Think Tank Title Sponsor Speakers:

• Shilpa Gupta, MD, Cleveland Clinic, representing Bristol Myers Squibb
• Andrea Ireland, PhD, Johnson & Johnson
• Dharanija Rao, PhD, Pfizer
• Mark Schoenberg, MD, UroGen Pharma
• Morganna Vance, MD, Gilead Sciences

BCAN-funded Investigator Speakers:

• Burles Johnson, MD, PhD, Johns Hopkins Medicine
• Neelam Mukherjee, PhD, University of Texas Health Center San Antonio
• Eugene Pietzak, MD, Memorial Sloan Kettering Cancer Center

Breakout Sessions

Advancements in Understanding Bladder Cancer Through Spontaneous Animal Models

Co-Chairs: Deborah W. Knapp DVM, MS, DACVIM (Oncology), Purdue University and Lauren Trepanier DVM, PhD, DACVIM (SAIM), DAVCP, University of Wisconsin-Madison

Exploring Research Rapid Autopsy Programs in Bladder Cancer: An Innovative Approach to Data Collection

Chairs: Petros Grivas, MD, PhD, University of Washington Medicine and Fred Hutchinson Cancer Center; and Andrew Hsieh, MD, Fred Hutchinson Cancer Center

Navigating the Emotional Landscape: Addressing Mental Health Challenges in Bladder Cancer Survivorship

Co-Chairs: Mary Dunn, MSN, NP-C, OCN, RN, University of North Carolina and Nihal Mohamed, PhD, Mount Sinai, and Krisztina Emodi, FNP, MPH, CNS, University of California San Francisco

Patient Engagement in Research

Co-Chairs: Angela B. Smith, MD, MS, University of North Carolina and John L. Gore, MD, MS, University of Washington

“Working” Smarter to Prevent Bladder Cancer: Unraveling Bladder Cancer’s Occupational and Environmental Threads

Co-Chairs: Sunil Patel, MD, MA, Johns Hopkins Medicine and Stella Koutros, PhD, MPH, National Cancer Institute

Navigating Young-Onset Bladder Cancer – From Genomics to Survivor Perspectives

Co-Chairs: Shilpa Gupta, MD, Cleveland Clinic, and Ashish Kamat, MD, MBBS, MD Anderson Cancer Center

Oligometastatic disease

Co-Chairs: Armine K. Smith, MD, Johns Hopkins Medicine, and Randy Sweis, MD, University of Chicago Medicine

Harnessing the Power of Artificial Intelligence in Advancing Bladder Cancer Research and Clinical Care

Co-Chairs: Bishoy M. Faltas, MD, Weill Cornell Medical College and Yair Lotan, MD, University of Texas, Southwestern Medical Center

2021 and 2022 Bladder Cancer Research Innovation Awardees

Introduction by Scientific Review Group Chair, Molly Ingersoll, PhD, , Institut Pasteur, Institut Cochin

• John K. Lee, MD, PhD, Fred Hutchinson Cancer Research Center: Inform new and effective treatment strategies for those suffering from variant bladder cancers
• Tyler J. Curiel, MD, MPH, Dartmouth-Hitchcock Clinic: Rationally engineered IL2 for enhanced treatment of local and metastatic bladder cancer
• John Sfakianos, MD, Icahn School of Medicine at Mount Sinai: High resolution molecular imaging to elucidate the contextual mechanisms of BCG resistance in non-muscle invasive recurrent bladder cancer

Striking a Balance: How much is too much bladder sparing therapy/surveillance?

Chairs: Roger Li MD, Moffit Cancer Center, and Mary Beth Westerman, MD, Louisiana State University

Breakout Sessions

Exploring the Evolving Landscape of Bladder Cancer Immunotherapy: Current Advances and Future Frontiers

Co-Chairs: Neelam Mukherjee, PhD, University of Texas Health Center San Antonio and Petros Grivas, MD, PhD., University of Washington Medical Center and Fred Hutchinson Cancer Center

Unveiling Innovations in Cognitive Resilience during Bladder Cancer Care with (P)Rehabilitation

Coming soon

Co-Chairs: Sarah Psutka, MD, MSc, and Hanna Hunter, MD, both from the University of Washington Medical Center and Fred Hutchinson Cancer Center

Excellence in Bladder Cancer in the Community: What are the key components for success?

Co-Chairs: Suzanne B. Merrill, MD, FACS, United Urology Group and Manojkumar Bupathi, MD, MS, Rocky Mountain Cancer Center

Cancer Nutrition and Microbiome Research

Co-Chairs: Laura Bukavina, MD, MPH, MSc, Cleveland Clinic and Amanda Nizam, MD, Cleveland Clinic

Advancing Understanding and Treatment of Urethral Carcinoma

Co-Chairs: BCAN Patient Advocate Bob Schreiber, Michael O’Donnell, MD, University of Iowa Hospitals & Clinics and Adam Feldman, MD, MPH, Massachusetts General Hospital

Quality of Life After Trimodality Therapy

Co-Chairs: Jason A. Efstathiou, MD, DPhil, FASTRO, FACRO, Massachusetts General Hospital and Matthew Mossanen, MD, MPH, Brigham and Women’s Hospital and Harvard Medical School

Between Germline and Tumor: The Aged Normal Urothelium

Co-Chairs: Philip Abbosh, MD, PhD, Fox Chase Cancer Center and Wendy Huss, PhD, Roswell Park Comprehensive Cancer Center

Emerging/Next Generation Imaging Technologies for Bladder Cancer

Coming soon

Chair: Omar Mian, MD, PhD, Cleveland Clinic